NOWDiagnostics | NOWDx

We are very pleased to announce that today, our First To Know® Syphilis Test received FDA De Novo Marketing Authorization for Over-the-Counter (OTC) Use. First To Know® is the first and only rapid syphilis test in the U.S. that provides an in-home result in 15 minutes with a single drop of blood. “FDA granting De Novo authorization of our First To Know® Syphilis Test could not have come at a more important juncture in our country’s efforts to slow the rise of syphilis. Testing is one of the most important tools we have in preventing the spread of sexually transmitted infections, and for the first time ever, consumers now have a fast and simple syphilis test that can be performed in the privacy of one’s home, with a result in minutes.” — Robert Weigle, CEO of NOWDx. "This FDA authorization is a significant milestone in addressing the syphilis epidemic. After reviewing the robust data from the clinical studies, I am impressed with the test's performance. There is a critical need to increase public awareness about the seriousness of untreated syphilis, especially in underserved and marginalized populations. An in-home test like this has the potential to greatly impact public health by improving access to timely detection and treatment." — Dr. Gregory Bledsoe, MD, MPH, MBA, former Surgeon General for Arkansas. Learn more about today’s announcement: https://lnkd.in/g47CWk6B #SyphilisTest #HealthAwareness #StayInformed #FirstToKnow #OverTheCounterTest #PublicHealth #EarlyDetection #HealthMatters #BeProactive #InHomeTesting

"An in-home test like this has the potential to greatly impact public health by improving access to timely detection and treatment." - said Dr. Gregory Bledsoe, MD, MPH, MBA, former Surgeon General for Arkansas 📰 New York Post, Deirdre Bardolf https://lnkd.in/e9Fs-mCN

“Access to home tests may help increase initial screening for syphilis, including in individuals who may be reluctant to see their health care provider about possible sexually transmitted infection exposure. This can lead to increased lab testing to confirm diagnosis, which can result in increased treatment and reduction in the spread of infection.” - Dr. Michelle Tarver, MD, PhD, acting director of the FDA’s Center for Devices and Radiological Health 📰 The Hill, Eden Teshome https://lnkd.in/e4JEYNWJ

NOWDx is committed to changing healthcare by providing accessible, affordable, and accurate testing for all. 📰 Yahoo, Kaitlin Reilly https://lnkd.in/g2Ck9R9n

"We have a great team who worked tirelessly to bring this product to market. They deserve all the credit. This simple first of its kind screening test could aid significantly in the fight to end this epidemic and bring down the rates of syphilis around the country by allowing anyone to test themselves in the privacy of their own home." - Robert Weigle, CEO of NOWDx 📰 ABC News, Mary Kekatos, Sony Salzman https://lnkd.in/g2J9UGHj

We are excited to announce that Susan Ward is stepping into the role of Director of Marketing at NOWDx, where she will lead strategic marketing and product management initiatives to elevate brand visibility and drive product growth. With her extensive expertise in IVD diagnostics, Susan will be focused on promoting the First To Know® Syphilis Test (https://bit.ly/3Au6EJL). #syphilis #test #marketing #newhire #testing #inhomeresult #diagnostics #nowdx #firsttoknow

We are thrilled to announce that T.J. Rivetti has joined our NOWDx leadership team as Director of Sales, Public Health. T.J. will cultivate relationships with public health departments and STI-funded agencies throughout the U.S. to achieve the sales goals of NOWDx, with a focus on our First To Know® Syphilis Test. #syphilis #test #publichealth #newhire #testing #inhomeresult #diagnostics #nowdx

First To Know® is the first and only rapid syphilis test in the U.S. that provides an in-home result in 15 minutes with a single drop of blood. NBC News https://lnkd.in/gVxjKYD3

“FDA granting De Novo authorization of our First To Know® Syphilis Test could not have come at a more important juncture in our country’s efforts to slow the rise of syphilis." - Robert Weigle, CEO of NOWDx. 📰 Conor Hale, Fierce Biotech https://lnkd.in/g-m8z2vg

"There is a critical need to increase public awareness about the seriousness of untreated syphilis, especially in underserved and marginalized populations. An in-home test like this has the potential to greatly impact public health by improving access to timely detection and treatment." - Dr. Gregory Bledsoe, MD, MPH, MBA, former Surgeon General for Arkansas First To Know 📰 The Washington Post, Rachel Roubein https://lnkd.in/gPMJE6B3